This first-in-human trial of an A2AR antagonist in cancer treatment underscores the antitumor potential of ciforadenant (CPI-444) both as a monotherapy and in combination with anti-PD-L1 in patients with refractory RCC. Here, ADORA2A is linked to renal cell carcinoma.